Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Routes of administration | Intramuscular |
KD-414 is a COVID-19 vaccine candidate developed by Japanese biotechnology company KM Biologics Co.[1][2][3] Results of a phase 1/2 clinical trial for this vaccine were released as a preprint in June 2022.[4]
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|